Efficacy And Safety Of Nintedanib In Patients With Idiopathic Pulmonary Fibrosis: Results Of Two 52-Week, Phase Iii, Randomized, Placebo-Controlled Trials (inpulsis™)

被引：0
|
作者：
Richeldi, L. [1 ]
Du Bois, R. [2 ]
Raghu, G. [3 ]
Azuma, A. [4 ]
Brown, K. K. [5 ]
Costabel, U. [6 ]
Cottin, V. [7 ]
Flaherty, K. [8 ]
Inoue, Y. [9 ]
Kim, D. [10 ]
Kolb, M. [11 ]
Noble, P. W. [12 ]
Selman, M. [13 ]
Taniguchi, H. [14 ]
Brun, M. [15 ]
Girard, M. [15 ]
Schlenker-Herceg, R. [16 ]
Disse, B. [17 ]
Collard, H. R. [18 ]
机构：
[1] Univ Southampton, Southampton, Hants, England
[2] Imperial Coll, London, England
[3] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[4] Nippon Med Sch, Tokyo, Japan
[5] Natl Jewish Hlth, Denver, CO USA
[6] Univ Duisburg Essen, Essen, Germany
[7] Univ Lyon, Lyon, France
[8] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[9] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Osaka, Japan
[10] Univ Ulsan, Asan Med Ctr, Seoul, South Korea
[11] McMaster Univ, Hamilton, ON, Canada
[12] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[13] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico
[14] Tosei Gen Hosp, Seto, Aichi, Japan
[15] Boehringer Ingelheim France SAS, Reims, France
[16] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[17] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[18] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6603
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: RESULTS OF TWO 52-WEEK, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIALS (INPULSIS™)
    Richeldi, L.
    Du Bois, R. M.
    Raghu, G.
    Azuma, A.
    Brown, K. K.
    Costabel, U.
    Cottin, V
    Flaherty, K. R.
    Inoue, Y.
    Kim, D. S.
    Kolb, M.
    Noble, P. W.
    Selman, M.
    Taniguchi, H.
    Brun, M.
    Girard, M.
    Schlenker-Herceg, R.
    Disse, B.
    Collard, H. R.
    RESPIROLOGY, 2014, 19 : 28 - 28
  • [2] Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis
    Richeldi, Luca
    Cottin, Vincent
    Flaherty, Kevin R.
    Kolb, Martin
    Inoue, Yoshikazu
    Raghu, Ganesh
    Taniguchi, Hiroyuki
    Hansell, David M.
    Nicholson, Andrew G.
    Le Maulf, Florence
    Stowasser, Susanne
    Collard, Harold R.
    RESPIRATORY MEDICINE, 2014, 108 (07) : 1023 - 1030
  • [3] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Serra-Baldrich, Esther
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Gil, Esther Garcia
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 740 - 748
  • [4] EFFICACY AND SAFETY OF TABALUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM 2 PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIALS
    Isenberg, D.
    Merrill, J.
    Hoffman, R.
    Linnik, M.
    Morgan-Cox, M.
    Veenhuizen, M.
    Iikuni, N.
    Dickson, C.
    Silk, M.
    Wallace, D.
    Doerner, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 141 - 141
  • [5] Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials
    Azuma, Arata
    Taniguchi, Hiroyuki
    Inoue, Yoshikazu
    Kondoh, Yasuhiro
    Ogura, Takashi
    Homma, Sakae
    Fujimoto, Tsuyoshi
    Sakamoto, Wataru
    Sugiyama, Yukihiko
    Nukiwa, Toshihiro
    RESPIROLOGY, 2017, 22 (04) : 750 - 757
  • [6] Efficacy and Safety of Nintedanib in US and Non-US Patients With Idiopathic Pulmonary Fibrosis (IPF) in the INPULSIS Trials
    Huggins, John
    Kaye, Mitchell
    Bailes, Zelie
    Esser, Dirk
    Conoscenti, Craig
    Flaherty, Kevin
    CHEST, 2015, 148 (04)
  • [7] Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)
    Blauvelt, Andrew
    Kimball, Alexa B.
    Augustin, Matthias
    Okubo, Yukari
    Witte, Michael M.
    Capriles, Claudia Rodriguez
    Sontag, Angelina
    Arora, Vipin
    Osuntokun, Olawale
    Strober, Bruce
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 866 - 877
  • [8] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
  • [9] The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial
    Clift, P.
    Berger, F.
    Sondergaard, L.
    Antonova, P.
    Disney, P.
    Nicolarsen, J.
    Thambo, J. -B.
    Pajak, L. Tomkiewicz
    Wang, J. -K.
    Jensen, A. Schophuus
    Burgess, G.
    Efficace, M.
    Friberg, M.
    Lassen, C.
    d'Udekem, Y.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1560 - 1560
  • [10] Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib
    Richeldi, Luca
    Crestani, Bruno
    Azuma, Arata
    Kolb, Martin
    Selman, Moises
    Stansen, Wibke
    Quaresma, Manuel
    Stowasser, Susanne
    Cottin, Vincent
    RESPIRATORY MEDICINE, 2019, 156 : 20 - 25
12345